Argentine consensus on the diagnosis and therapeutics of treatment resistant schizophrenia
DOI:
https://doi.org/10.53680/vertex.v32i154.119Keywords:
Schizophrenia, Treatment-resistant schizophrenia, Expert consensus, Treatment recommendation, Psychosocial intervention, Antipsychotics, First generation antipsychotics, Second generation antipsychotics, Clozapine, Electroconvulsive therapyAbstract
Approximately 30% of people with schizophrenia fail to respond to first-line antipsychotic treatment which impacts the burden of the disease. Treatment resistant schizophrenia denotes patients with failure to respond to at least two
adequate trials of different antipsychotics. Clozapine is a unique drug approved for treating treatment-resistant schizophrenia, however 1/3 of patients fail to respond to clozapine. Even though different strategies have been proposed for treating clozapine-resistant schizophrenia, the evidence is very limited, unclear, and of poor quality. A formal literature search was conducted and then, panel members were asked to complete
35 questions addressing different aspects of ERT.
A modified Delphi method was used to unify expert opinion and achieve consensus. The expert
consensus in diagnostic and treatment of TRS is
the result of experts from the main national scientific societies under the organization of the Argentine Association of Biological Psychiatric
AAPB. The consensus statement aims to guide on diagnosis and treatment.
Downloads
